#185: Carvedilol superior to metoprolol in MADIT-CRT analysis; FDA approves new diabetes drug, canagliflozin, despite CV concerns; heart-smart diabetes drugs; more beaches, less bureaucracy, say burned out cardiologists
Carvedilol superior to metoprolol in MADIT-CRT analysis; FDA approves new diabetes drug, canagliflozin, despite CV concerns; heart-smart diabetes drugs; more beaches, less bureaucracy, say burned out cardiologists
Source: Blogs@theHeart.org - Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: blogs
More News: Blogging | Burns | Canagliflozin | Cardiology | Coreg | Diabetes | Endocrinology | Heart | Invokana | Toprol